Year: 2024
Type: review
Abstract: Lung cancer is the most prevalent malignant tumour in the Asia–Pacific region. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancers. Among these, the rate of EGFR mutations in Asian patients with lung adenocarcinoma is 40–60%. Third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs) have improved the clinical management of NSCLC with EGFR mutations, but resistance to these drugs remains a significant challenge. Despite numerous ongoing studies, there is no standardized consensus on managing resistance to third-generation EGFR-TKIs. This consensus integrates international guidelines on EGFR-TKI management, findings from clinical studies, and experiences from the Asia–Pacific region in addressing post-resistance. Detailed recommendations are provided for classification and progression patterns, clinical testing, and post-resistance treatment strategies related to third-generation EGFR-TKI resistance. The aim of these recommendations is to offer reference opinions for the standardized management of patients exhibiting resistance to third-generation EGFR-TKIs in clinical practice.
Institutions: Guangdong Academy of Medical Sciences, Guangdong Provincial People's Hospital, Southern Medical University, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Shanghai Jiao Tong University, Shanghai Chest Hospital, Jilin Province Tumor Hospital, First Hospital of China Medical University, Affiliated Hospital of Qingdao University, Xiangya Hospital Central South University, Peking Union Medical College Hospital, Peking University, Peking University People's Hospital, Peking University Cancer Hospital, Jiangsu Province Hospital, Liaoning Cancer Hospital & Institute, First Affiliated Hospital of Anhui Medical University, Wuhan Union Hospital, Huazhong University of Science and Technology, First Hospital of Jilin University, First Bethune Hospital of Jilin University, National Cancer Centre Singapore, Samsung Medical Center, National Cancer Center Hospital East, Chinese University of Hong Kong
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,680
Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Regeneron Pharmaceuticals, Taiho Pharmaceutical, BeiGene, G1 Therapeutics, Bayer HealthCare, National Natural Science Foundation of China, Daiichi-Sankyo, Eisai, Southern Medical University, Ono Pharmaceutical, Da Volterra, Chugai Pharmaceutical, Eli Lilly Japan, Medtronic Japan, Daiichi Sankyo Europe
OpenAlex ID: W4405231483